Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA
Biotech
FDA snubs Fortress' Zydus-partnered Menkes disease candidate
Sentynl and Cyprium were angling the drug candidate to be the first approved treatment for a rare, often fatal pediatric disease.
Zoey Becker
Oct 1, 2025 12:00pm
Siemens Healthineers’ MRIs see FDA recall over ice blockages
Oct 1, 2025 10:30am
FDA clears Biolinq's color-coded sensor patch for glucose ranges
Sep 29, 2025 11:30am
Applied Tx's stock drops on non-update for rare disease asset
Sep 29, 2025 10:57am
FDA clears 1st eyeglasses for slowing childhood nearsightedness
Sep 26, 2025 11:38am
Heartflow's updated coronary plaque AI nets FDA clearance
Sep 24, 2025 12:00pm